These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29247263)

  • 41. The role of tissue diagnosis prior to neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
    Daniel ES; Gibbs P; Guerrieri M; Faragher I
    Colorectal Dis; 2014 Oct; 16(10):783-7. PubMed ID: 24786681
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer.
    Pucciarelli S; Capirci C; Emanuele U; Toppan P; Friso ML; Pennelli GM; Crepaldi G; Pasetto L; Nitti D; Lise M
    Ann Surg Oncol; 2005 Feb; 12(2):111-6. PubMed ID: 15827790
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pathologic Complete Response Rates After Neoadjuvant Treatment in Rectal Cancer: An Analysis of the National Cancer Database.
    Lorimer PD; Motz BM; Kirks RC; Boselli DM; Walsh KK; Prabhu RS; Hill JS; Salo JC
    Ann Surg Oncol; 2017 Aug; 24(8):2095-2103. PubMed ID: 28534080
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Downstaging after chemoradiotherapy for locally advanced rectal cancer: is there more (tumor) than meets the eye?
    Mignanelli ED; de Campos-Lobato LF; Stocchi L; Lavery IC; Dietz DW
    Dis Colon Rectum; 2010 Mar; 53(3):251-6. PubMed ID: 20173469
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Pretreatment Systemic Inflammatory Response is an Important Determinant of Poor Pathologic Response for Patients Undergoing Neoadjuvant Therapy for Rectal Cancer.
    Dreyer SB; Powell AG; McSorley ST; Waterston A; Going JJ; Edwards J; McMillan DC; Horgan PG
    Ann Surg Oncol; 2017 May; 24(5):1295-1303. PubMed ID: 27873100
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center.
    Zhou J; Qiu H; Lin G; Xiao Y; Wu B; Wu W; Sun X; Lu J; Zhang G; Xu L; Liu Y
    Int J Colorectal Dis; 2016 Jun; 31(6):1163-8. PubMed ID: 27044403
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis.
    Tan Y; Fu D; Li D; Kong X; Jiang K; Chen L; Yuan Y; Ding K
    Front Oncol; 2019; 9():497. PubMed ID: 31263674
    [No Abstract]   [Full Text] [Related]  

  • 48. Delaying surgery after neoadjuvant chemoradiotherapy in rectal cancer has no influence in surgical approach or short-term clinical outcomes.
    Figueiredo N; Panteleimonitis S; Popeskou S; Cunha JF; Qureshi T; Beets GL; Heald RJ; Parvaiz A
    Eur J Surg Oncol; 2018 Apr; 44(4):484-489. PubMed ID: 29398323
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Wait-and-see or radical surgery for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy: a cohort study.
    Li J; Liu H; Yin J; Liu S; Hu J; Du F; Yuan J; Lv B; Fan J; Leng S; Zhang X
    Oncotarget; 2015 Dec; 6(39):42354-61. PubMed ID: 26472284
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A scoring system basing pathological parameters to predict regional lymph node metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer: implication for local excision.
    Wang XJ; Chi P; Lin HM; Lu XR; Huang Y; Xu ZB; Huang SH; Sun YW; Ye DX; Yu Q
    Oncotarget; 2016 Nov; 7(48):78487-78498. PubMed ID: 27489356
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial.
    Fokas E; Liersch T; Fietkau R; Hohenberger W; Beissbarth T; Hess C; Becker H; Ghadimi M; Mrak K; Merkel S; Raab HR; Sauer R; Wittekind C; Rödel C
    J Clin Oncol; 2014 May; 32(15):1554-62. PubMed ID: 24752056
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prediction of Pathological Complete Response Using Endoscopic Findings and Outcomes of Patients Who Underwent Watchful Waiting After Chemoradiotherapy for Rectal Cancer.
    Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Morikawa T; Fukayama M; Watanabe T
    Dis Colon Rectum; 2017 Apr; 60(4):368-375. PubMed ID: 28267003
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oncologic results and prognostic predictors of patients with locally advanced rectal cancer showing ypN0 after radical surgery following neoadjuvant chemoradiotherapy.
    Lee KH; Kim JC; Kim JY; Kim JS
    Int J Colorectal Dis; 2015 Aug; 30(8):1041-50. PubMed ID: 26002751
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Implications of lymph node retrieval in locoregional rectal cancer treated with chemoradiotherapy: a California Cancer Registry Study.
    Gill A; Brunson A; Lara P; Khatri V; Semrad TJ
    Eur J Surg Oncol; 2015 May; 41(5):647-52. PubMed ID: 25800934
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Complete Pathological Response After Neoadjuvant Long-Course Chemoradiotherapy for Rectal Cancer and Its Relationship to the Degree of T3 Mesorectal Invasion.
    Wilkins S; Haydon A; Porter I; Oliva K; Staples M; Carne P; McMurrick P; Bell S
    Dis Colon Rectum; 2016 May; 59(5):361-8. PubMed ID: 27050597
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
    Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
    Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NPTX2 is associated with neoadjuvant therapy response in rectal cancer.
    Karagkounis G; Thai L; DeVecchio J; Gantt GA; Duraes L; Pai RK; Kalady MF
    J Surg Res; 2016 May; 202(1):112-7. PubMed ID: 27083956
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients.
    Lopes-Ramos CM; Habr-Gama A; Quevedo Bde S; Felício NM; Bettoni F; Koyama FC; Asprino PF; Galante PA; Gama-Rodrigues J; Camargo AA; Perez RO; Parmigiani RB
    BMC Med Genomics; 2014 Dec; 7():68. PubMed ID: 25496125
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of oncologic outcomes of metastatic rectal cancer patients with or without neoadjuvant chemoradiotherapy.
    Kim SH; Kim JH; Jung SH
    Int J Colorectal Dis; 2015 Sep; 30(9):1193-9. PubMed ID: 26072129
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oncologic Outcomes according to the Treatment Strategy in Radiologic Complete Responders after Neoadjuvant Chemoradiation for Rectal Cancer.
    Lee SY; Kim CH; Kim YJ; Kim HR
    Oncology; 2015; 89(6):311-8. PubMed ID: 26426305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.